For its third fiscal quarter (ending September 30), Zimmer Biomet Holdings Inc (NYSE: ZBH) has reported a -15% decline in E.P.S. from $0.92 a year ago to $0.78 in the current quarter. This performance was $-0.82 short of the consensus estimate of $1.60. E.P.S. were $2.27 for the latest four quarters through September 30 versus $1.75 for the same period a year ago — an increase of 30%.
Recent Price Action
On 11/7/23, Zimmer Biomet Holdings Inc (NYSE: ZBH) stock suffered a large decline of -3.1%, closing at $105.93. The stock has performed in line with the market over the last nine months and has risen 2.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, ZBH is expected to continue to be an important Value Builder.
Zimmer Biomet Holdings has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Zimmer Biomet Holdings has a neutral Power Rating of 45 and a slightly negative Appreciation Score of 32, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment